Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10372
Title: Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial.
Authors: Manley, Karen J;Fraenkel, Margaret B;Mayall, Barrie C;Power, David Anthony
Affiliation: Austin Health, Melbourne, Victoria, Australia. karen.manley@austin.org.au
Issue Date: 7-May-2007
Citation: Medical Journal of Australia; 186(9): 454-7
Abstract: To determine whether eating Lactobacillus rhamnosus GG (LGG) in the form of commercially available yoghurt improves clearance of vancomycin-resistant enterococci (VRE).Double-blind, randomised, placebo-controlled trial.Renal ward of Austin Health, a tertiary hospital, Feb-Oct 2005.27 VRE-positive patients, 14 receiving active treatment and 13 controls.Subjects were randomly assigned to either a treatment group (receiving 100 g daily of yoghurt containing LGG for 4 weeks) or a control group (receiving standard pasteurised yoghurt). Faecal samples were obtained three times at about weekly intervals. Treated patients were tested for VRE again at 8 weeks. Patients in the control group who had failed to clear VRE after 4 weeks were then given LGG-containing yoghurt for 4 weeks, as an open continuation.Number of faecal specimens clear of VRE.Of the 27 patients enrolled, 23 completed the study. Two patients were lost to follow-up, one died and one withdrew. All 11 patients in the treatment group who completed the study cleared VRE. Three subjects reverted to VRE positivity after using antibiotics to which LGG is sensitive, while all others remained negative for at least 4 weeks after trial completion. Twelve control subjects completed the study, of whom one cleared VRE and 11 remained VRE-positive. Eight of these 11 patients were subsequently crossed over to receive LGG yoghurt, and all cleared VRE within 4 weeks.To our knowledge, this is the first description of a probiotic therapy to successfully treat gastrointestinal carriage of VRE in renal patients. Further investigation of the use of LGG in VRE-positive patients is warranted.
Internal ID Number: 17484706
URI: http://ahro.austin.org.au/austinjspui/handle/1/10372
URL: http://www.ncbi.nlm.nih.gov/pubmed/17484706
Type: Journal Article
Subjects: Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents.therapeutic use
Cross-Over Studies
Double-Blind Method
Drug Utilization
Enterococcus
Feces.microbiology
Female
Gram-Positive Bacterial Infections.therapy
Humans
Lactobacillus rhamnosus
Male
Middle Aged
Probiotics.therapeutic use
Renal Insufficiency.complications
Treatment Outcome
Vancomycin Resistance
Yogurt.microbiology
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.